Evidence map›Paper›PMID 32101146›Full record

ArticleJournal of nanobiotechnology2020

Manipulation of macrophage polarization by peptide-coated gold nanoparticles and its protective effects on acute lung injury.

Lu Wang, Huasheng Zhang, Liya Sun, Wei Gao, Ye Xiong, Aying Ma, Xiali Liu, Lei Shen, Qiang Li, Hong Yang

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 139 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Macrophage Polarization Profiling in Dynamic Culture System.Cellular and molecular bioengineering · 2025
    Article
  17. Review
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Lu WangDepartment of Pulmonary and Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201620, China.
Huasheng ZhangShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Liya SunSchool of Biomedical Engineering, Tianjin Medical University, Tianjin, 300070, China.
Wei GaoDepartment of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, 200120, China.
Ye XiongDepartment of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, 200120, China.
Aying MaDepartment of Pulmonary and Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201620, China.
Xiali LiuDepartment of Pulmonary and Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201620, China.
Lei ShenShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. lshen@shsmu.edu.cn.
Qiang LiDepartment of Pulmonary and Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201620, China. liqressh@hotmail.com.
Hong YangDepartment of Pulmonary and Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201620, China. hongyang@tmu.edu.cn.
Shanghai Jiao Tong University · CNShanghai East Hospital · CNTianjin Medical University · CNShanghai First People's Hospital · CN

Funding

National Natural Science Foundation of China 81770070National Natural Science Foundation of China 81870064Outstanding Clinical Discipline Project of Shanghai Pudong PWYgy2018-06Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning TP2016014Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support 20171923
6 · The paper itself

Abstract

backgroundMacrophage polarization and reprogramming in the lung play a critical role in the initiation, development and progression of acute lung injury (ALI). Regulating the activation and differentiation of pulmonary macrophages may provide a potential therapeutic strategy to treat ALI. We previously developed a novel class of anti-inflammatory nanoparticles (P12) that can potently inhibit Toll-like receptor (TLR) signaling in macrophages. These bioactive nanodevices were made of gold nanoparticles (GNPs) coated with hexapeptides to not only ensure their physiological stability but also enable GNPs with TLR inhibitory activity.

resultsIn this study, using a lipopolysaccharide (LPS) induced ALI mouse model, we showed that P12 was able to alleviate lung inflammation and damage through reducing the infiltration of inflammatory cells and increasing the anti-inflammatory cytokine (IL-10) in the lung. These results prompted us to investigate possible macrophage polarization by P12. We first confirmed that P12 primarily targeted macrophages in the lung to exert anti-inflammatory activity. We then showed that P12 could drive the polarization of mouse bone marrow-derived macrophages (BMDMs) toward anti-inflammatory M2 phenotype. Interestingly, in the ALI mouse model, P12 was able to increase the alveolar M2 macrophages and reduce both the alveolar and interstitial M1 macrophages in the bronchoalveolar lavage fluid (BALF) and lung tissues.

conclusionThis study demonstrated that peptide-coated GNPs could induce M2 macrophage polarization in vitro and in vivo to effectively regulate lung inflammation, protect lung from injuries and promote inflammation resolution. The ability of regulating macrophage polarization together with TLR inhibition made such a bioactive nanodevice a new generation of potent therapeutics to treat ALI.

Indexed as

Acute Lung InjuryAnimalsAnti-Inflammatory AgentsBronchoalveolar Lavage FluidDisease Models, AnimalGoldInterleukin-10LipopolysaccharidesLungMacrophagesMaleMetal NanoparticlesMiceMice, Inbred C57BLPneumoniaAnti-Inflammatory AgentsGoldInterleukin-10LipopolysaccharidesAcute lung injuryAlveolar macrophageGold nanoparticleInflammationMacrophage polarizationPeptide

Identifiers

PMID32101146
PMCPMC7045427
OpenAlexW3009943710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.